Virtue Capital Management LLC Sells 294 Shares of Stryker Corporation $SYK

Virtue Capital Management LLC lowered its stake in Stryker Corporation (NYSE:SYK) by 33.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 587 shares of the medical technology company’s stock after selling 294 shares during the quarter. Virtue Capital Management LLC’s holdings in Stryker were worth $232,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC boosted its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Assetmark Inc. increased its position in shares of Stryker by 28.4% in the first quarter. Assetmark Inc. now owns 1,667 shares of the medical technology company’s stock valued at $621,000 after acquiring an additional 369 shares during the period. Arkadios Wealth Advisors raised its stake in shares of Stryker by 495.9% during the first quarter. Arkadios Wealth Advisors now owns 4,052 shares of the medical technology company’s stock valued at $1,508,000 after acquiring an additional 3,372 shares during the last quarter. MONECO Advisors LLC boosted its holdings in shares of Stryker by 5.9% during the first quarter. MONECO Advisors LLC now owns 2,156 shares of the medical technology company’s stock worth $802,000 after purchasing an additional 121 shares during the period. Finally, Baker Avenue Asset Management LP grew its stake in shares of Stryker by 7.7% in the first quarter. Baker Avenue Asset Management LP now owns 1,960 shares of the medical technology company’s stock worth $730,000 after purchasing an additional 140 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $371.29 on Friday. The company has a market capitalization of $141.99 billion, a P/E ratio of 49.18, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $368.90 and a 200 day moving average of $380.26.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter last year, the company earned $2.87 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

SYK has been the topic of a number of research analyst reports. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Needham & Company LLC reiterated a “buy” rating and set a $448.00 price target on shares of Stryker in a research report on Friday, November 14th. Truist Financial raised their price objective on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a report on Friday, November 14th. UBS Group set a $408.00 price objective on Stryker in a research report on Monday, October 13th. Finally, Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 522,118 shares of company stock worth $185,381,932 over the last three months. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.